Although combination therapy with anti-PD-1 antibodies and the Anchored GM-CSF vaccine could effectively reduce tumor growth and improve the cytotoxic activity of CTLs relative to monotherapy, tumor regression occurred in only a few mice, and the majority of subcutaneous tumors continued to grow slowly. The gene discussed is CSF2; the disease is neoplasm.